Most gastrointestinal stromal tumors (GISTs) can be recognized by their monotonous cytologic features and overexpression of KIT oncoprotein. Altered morphology and loss of CD117 reactivity has been described previously after chronic imatinib treatment; however, this phenomenon has not been reported in imatinib-naive tumors. Eight patients with abrupt transition from a classic CD117-positive spindle cell GIST to an anaplastic CD117-negative tumor were investigated for underlying molecular mechanisms of tumor progression. Pathologic and molecular analysis was performed on each of the 2 components. Genomic DNA polymerase chain reaction for KIT, PDGFRA, BRAF, and KRAS hot spot mutations and fluorescence in situ hybridization for detecting KIT gene copy number alterations were performed. TP53 mutational analysis was performed in 5 cases. There were 7 men and 1 woman, with an age range of 23 to 65 years. Five of the primary tumors were located in the stomach, and 1 case each originated in the small bowel, colon, and rectum. In 3 patients, the dedifferentiated component occurred in the setting of imatinib resistance, whereas the remaining 5 occurred de novo. The dedifferentiated component had an anaplastic appearance, including 1 angiosarcomatous phenotype, with high mitotic activity and necrosis, and showed complete loss of CD117 (8/8) and CD34 (5/8) ex-pression and de novo expression of either cytokeratin (4/8) or desmin (1/8). There was no difference in the KIT genotype between the 2 components. However, 2 imatinib-resistant tumors showed coexistence of KIT exon 11 and exon 13 mutations. Fluorescence in situ hybridization showed loss of 1 KIT gene in 3 cases and low-level amplification of KIT in 2 other cases in the CD117-negative component, compared with the CD117-positive area. TP53 mutation was identified in 1/5 cases tested, being present in both components. In summary, dedifferentiation in GIST may occur either de novo or after chronic imatinib exposure and can represent a diagnostic pitfall. This phenomenon is not related to additional KIT mutations, but might be secondary to genetic instability, either represented by loss of heterozygosity or low level of KIT amplification.
desmin or both. 8, 9 So far this phenomenon has not been reported in imatinib-naive tumors, and dedifferentiation, although well described in other sarcoma types, has not been well characterized in GIST.
We have identified 8 patients with abrupt transition from a classic CD117-positive spindle cell GIST to anaplastic CD117-negative tumor, in which we sought to investigate the underlying molecular mechanisms of tumor progression. A comparative morphologic, immunohistochemical, and molecular investigation was undertaken of both GIST components, to better define diagnostic pitfalls, morphologic and molecular features, and possible pathogenesis. We also investigated whether progression from a CD117-positive classic appearance to a CD117-negative anaplastic phenotype might be related to the history of imatinib therapy, perhaps being secondary to the development of imatinib resistance.
MATERIALS AND METHODS
The pathology files of 5 different institutions (Brigham&Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA; Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China; Treviso General Hospital, Treviso, Italy; and Memorial Sloan-Kettering Cancer Center, New York, NY) were searched for a diagnosis of anaplastic or dedifferentiated GIST. Eight cases were identified in which a CD117-positive GIST component with a classic morphologic appearance was juxtaposed to a CD117negative anaplastic or pleomorphic-type neoplasm.
Morphology and Immunohistochemistry
The 2 morphologically and immunophenotypically distinct components were analyzed separately. The morphologic appearance of the CD117-positive classic GIST was classified as predominantly spindle, epithelioid, or mixed. The degree of nuclear pleomorphism and presence of giant cells were scored in each component. A mitotic count per 50 HPF was recorded independently in each area. Immunohistochemical studies for the following antibodies were performed: CD117, CD34, desmin, cytokeratin, and p53, and scored independently in each component.
KIT/PDGFRA Genotyping for Primary and Secondary Mutations
Mutational analysis was performed using standard protocols. Genomic DNA was isolated separately from each macrodissected component from paraffin-embedded tissue. All 16 samples from the 8 patients were tested for the known sites of KIT (exons 9, 11, 13, 14, and 17), PDGFRA (exons 12 and 18), BRAF exon 15, and KRAS exon 2. One microgram of genomic DNA was subjected to polymerase chain reaction (PCR) using Platinum TaqDNA Polymerase High Fidelity (Life Technologies Inc., Gaithersburg, MD). Primer sequences and annealing temperatures for KIT, PDGFRA, and BRAF were as described. 7, 10 The KRAS primers used were: KRAS-Ex2Fwd: 5 0 -GTGTGACATGTTCTAATATAGT CA-3 0 , KRAS-Ex2Rev: 5 0 -GTGCAGGACCATTCTTTG ATACAG-3 0 . Direct sequencing of PCR products was performed for all exons tested, and each ABI sequence was compared with the NCBI human KIT and PDGFRA gene sequences (NM_000222.2 and NM_006197.1, respectively).
TP53 Mutation Analysis
Mutation analysis was performed in 5 cases by DNA PCR using 1 mg of genomic DNA extracted from microdissected formalin-fixed paraffin-embedded tissue from each component. The main hot-spots for p53 mutations were screened, including exons 5 to 8. Primer sequences and annealing temperatures were used as previously reported. 7 
Fluorescence In Situ Hybridization Analysis for KIT/PDGFRA Copy Number Changes
Fluorescence in situ hybridization (FISH) was performed in 7 cases, using formalin-fixed paraffin-embedded sections according to standard procedures. Each of the 2 components, identified on a matching hematoxylin and eosin slide, was analyzed and scored separately. Briefly, paraffin sections were dewaxed in xylene and then microwaved in 10 mM sodium citrate (pH 6 to 6.5) solution for 5 to 10 minutes, cooled to room temperature, rinsed, and dehydrated. The slides were then denatured in 70% formamide at 681C for 2 to 4 minutes, quenched, dehydrated, and air-dried. The KIT probes used were 2 overlapping BAC clones: CTD-3180G20 and RP11-722F21 (Invitrogen), labeled by nick-translation with Spectrum Green (Vysis, Abbott Laboratories, IL). The PDGFRA probes used included 2 BAC clones that spanned about 290 kbp around the gene: RP11-117E8 and RP11-231C18 (Invitrogen). A chromosome 4 centromeric probe labeled with Spectrum Orange (CEP4; Vysis) was used as reference. The probe mix, 50 to 80 ng of each KIT or PDGFRA BAC and 2 AL Cot-1 DNA (Invitrogen), was ethanol precipitated, and resuspended in hybridization buffer. The KIT or PDGFRA probe mix was denatured at 701C for 10 minutes, followed by preannealing at 371C for 30 minutes. The KIT or PDGFRA probe was then combined with the denatured CEP4 probe on the slide, cover slipped, and incubated overnight at 371C. After standard posthybridization washes, the slides were stained with 4', 6-diamidino-2-phenylindole and mounted in antifade (Vectashield, Vector Laboratories). Analysis was done using a Nikon E800 epifluorescence microscope with Isis 3 imaging software (MetaSystems). A minimum of 100 cells was scanned over separate regions for each slide. Z-stack images were captured using a Zeiss Axioplan 2 motorized microscope controlled by Isis 5 software (Metasystems).
RESULTS

Demographics and Imatinib Therapy Information
There were 7 men and 1 woman, with a wide age distribution at diagnosis, ranging from 23 to 65 years (mean, 50 y) ( Table 1 ). The only female patient included in this series was pregnant in her second trimester when the diagnosis was rendered. Primary tumors were located mostly in the stomach in 5 cases, and 1 case each originated from the small bowel, colon, and rectum. Primary tumor size ranged from 5.5 to 25 cm. Among the 4 patients presenting with localized disease at diagnosis, 3 were classified as high risk for metastasis and 1 intermediate risk by National Comprehensive Cancer Network criteria. 11 In 2 of the patients with high-risk disease, the disease recurred in the peritoneum or liver, for which the patients received imatinib therapy for 40 and 48 months, respectively, before progressing clinically and being debulked surgically (cases 7 and 8). Four patients had metastatic implants at diagnosis, 3 of them being debulked without prior imatinib therapy, whereas 1 patient received neoadjuvant imatinib, having being deemed inoperable and subsequently biopsied after progression developed. Thus, all 3 examples of imatinib therapyinduced dedifferentiation occurred in the clinical setting of imatinib-resistant disease.
One additional patient was identified and analyzed separately from the study group, as only the CD117negative anaplastic component was present in the resection specimen, without a classic CD117-positive component. This patient, a 66-year-old man, was diagnosed with chronic myeloid leukemia (CML) in 1998 and treated with imatinib for 10 years, and in 2010 he developed cytogenetic relapse. After 1 year on nilotinib, which was not well tolerated, he was switched to dasatinib for a short period, during which he developed massive upper gastrointestinal bleeding and was diagnosed with a small-bowel lesion with liver and peritoneal metastases. The palliative surgical resection showed an anaplastic tumor with epithelioid and rhabdoid morphology, with high mitotic count and necrosis. The immunohistochemical studies showed focal cytokeratin positivity, whereas CD117 and DOG1 were negative. The diagnosis of GIST was confirmed on the basis of molecular demonstration of a KIT exon 11 WK557-8 deletion. Table 2 ). There was no difference noted in the morphologic appearance of the dedifferentiated component, whether it occurred de novo or secondary to imatinib therapy ( Table 2 ). In 1 tumor (case #7, Fig. 3D ) the CD117-negative anaplastic component showed irregular, slit-like vascular spaces, lined by hyperchromatic and anaplastic tumor cells, which were reminiscent of angiosarcoma. This component was positive for CD31 ( Fig. 3F ) and CD34 and was negative for CD117 ( Fig. 3E ). To the best of our knowledge, this is the first example of GIST demonstrating differentiation toward an endothelial lineage.
Morphology and Immunohistochemistry
Molecular Analyses
There was no difference in the KIT genotype between the 2 components analyzed. In 4 patients their tumors had a KIT, PDGFRA, and BRAF wild-type genotype in both components, for all hot-spot exons tested ( Table 3 ). The remaining 4 tumors exhibited a KIT exon 11 mutation: WK557-8 deletion in 2 cases, a K550-W557 29 bp deletion (including deletion of 6 nucleotides from intron 10 and 23 nucleotides from exon 11) in 1 case, and a V559G substitution in the fourth case. These last 2 KIT exon 11 genotypes were detected in the dedifferentiated GIST secondary to imatinib therapy; in both of these cases an additional KIT exon 13 mutation was detected ( Table 3 ). In case #7, the primary tumor (resected in 1998) and the subsequent recurrence (2001), both imatinib naive, had only the KIT exon 11 V559G mutation. However, the resistant disease resected after 40 months on therapy (2005) showed an additional secondary KIT exon 13 V654A mutation in both CD117-negative (angiosarcomatous morphology) and CD117-positive components. Compared with the imatinib-naive heterozygous pattern, both KIT exon 11 and 13 mutations showed a homozygous pattern in the imatinib-resistant samples (in both CD117-positive/negative components), consistent with loss of heterozygosity (LOH) at this locus. This result was further confirmed by FISH, which detected only 1 KIT signal compared with the normal CEP4 pattern (see below). Case #8 showed 1 base-pair insertion in exon 13, V643Sfs6*, resulting in a truncating frame-shift mutation, which was detected in both the imatinib-naive primary tumor (resected from 2008) and the imatinib-resistant tumor (debulked in 2011), but not in the patient's normal blood DNA. The possibility of this mutation being present at the genomic DNA level only, while being removed from the transcript by nonsense-mediated decay, and therefore not detectable at the cDNA level, could not be ruled out, as we were not able to obtain good-quality RNA for validating this mutation. The third patient in whom the CD117-negative component was detected after imatinib therapy had a wild-type genotype. The anaplastic KIT-negative GIST occurring in the patient with long-term imatinib therapy for CML showed a concomitant KRAS G12V mutation to the KIT exon 11. As there was no associated CD117-positive, morphologically bland, spindle cell component or tissue available from the specimen before imatinib therapy, we cannot establish whether the presence of the KRAS G12V mutation is secondary to imatinib therapy or related to the CD117-negative dedifferentiation phenotype. As a consequence of this finding we have studied all the other cases for mutations at this hot spot; however, no other dedifferentiated GIST showed this abnormality. Also, no mutations were identified in BRAF exon 15 in any of the cases tested. TP53 mutation was identified in only 1 of the 5 cases tested (case #4). The same mutation was present in both components.
FISH showed loss of 1 KIT gene copy in the dedifferentiated component in all 3 cases that occurred secondary to imatinib therapy (Fig. 1K) , whereas the CD117-positive component of the imatinib-resistant GIST showed 2 normal copies, detected by 2 CEP4 signals ( Fig. 1H ). This result was also confirmed by comparing the ABI sequencing of intron 17 of the 2 components in these 3 cases, showing LOH in the dedifferentiated component, whereas the CD117-positive area genotype retained the heterozygous pattern of common SNP present in this region (Figs. 1I, L) . In addition, a low level of KIT amplification was detected in 2 of 3 de novo dedifferentiated GIST tumors, compared with the CD117-positive components with classic morphology (Figs. 2I-K).
DISCUSSION
Dedifferentiation was first described in chondrosarcoma, 12 wherein a low-grade chondrosarcoma component is juxtaposed to an anaplastic, nonchondroid, spindle, and often pleomorphic sarcomatous component. Subsequent examples of dedifferentiation have been described in liposarcoma, leiomyosarcoma, solitary fibrous tumor, etc. [13] [14] [15] However, all these examples have been described de novo, unrelated to the use of therapeutic agents (chemotherapy, radiation, etc.), occurring most likely because of acquisition of secondary genetic events, which trigger tumor progression and induce phenotypic muscle differentiation (desmin and myogenin reactivity). 9 In at least a subset of these cases, secondary BRAF mutations have been implicated in the mechanism of inducing imatinib resistance. 10 However, no BRAF mutations were detected in any of the dedifferentiated GIST cases tested in our study.
One of the pitfalls encountered when confronted with 2 very different morphologies is the possibility of a collision between a conventional GIST and a different neoplasm. That was the case in our case #1, in which the referring pathologist questioned the possibility of a carcinoma next to the peritoneal GIST recurrence. It is likely that the case recently reported as a collision between a giant cell-rich leiomyosarcoma and GIST also represents an example of a dedifferentiated GIST. 16 Another potential diagnostic pitfall is the nonrandom association of GIST with desmoid-type fibromatosis. 17 As these lesions may express weak/focal CD117 reactivity, they can be confused with recurrent/progressing GIST. Conversely, on the basis of their negative CD117 expression, these tumors, when growing on imatinib therapy, could potentially be misinterpreted as CD117-negative imatinib-resistant GIST. However, the characteristic uniform fascicular spindle cell appearance of desmoid tumors, with distinctive myofibroblastic differentiation, is very different from the anaplastic and pleomorphic areas of dedifferentiation described here.
KRAS mutations have been implicated recently as a mechanism of primary resistance, being reported in 3 of 60 (5%) GIST patients and coexisting with imatinibsensitive KIT or PDGFRA mutations in naive GIST. 18 Although none of these patients have in fact been treated with imatinib to explore the impact of concomitant KRAS mutations on clinical response, in vitro studies suggested that imatinib treatment of KITD559/KRAS double mutants only partially reduced the phosphorylation levels of ERK1/2 and AKT. 18 Interestingly, a KRAS G12V mutation was identified in one of the dedifferentiated GIST tumors; however, its significance in inducing this phenotype remains unclear, as it was not present in the other cases.
Although TP53 mutations have frequently been implicated in driving tumor progression and leading to genomic instability, 19 it does not seem to play an important role in KIT-independent dedifferentiation, as it was detected in only 1 of the clinically advanced cases in our series and was present in both components.
Most mechanisms of drug resistance in GIST relieve the imatinib-induced apoptotic effect by reactivating the original driving oncogene, KIT, through either secondary mutations or yet unidentified pathways (so-called "functional resistance"). Thus, most imatinib-resistant GISTs remain dependent on KIT for cell proliferation and show hyperactivation of the KIT receptor. The acquisition of secondary KIT mutations on the same allele as the primary mutation is the prevailing mechanism of failure, which typically occurs after a prolonged interval of KIT inhibition (of at least a year). 20, 21 In contrast, acquired resistance in tumors lacking detectable second-site mutations occurs in patients who have been on the drug for a shorter period of time. 20 Only occasionally does imatinib resistance occur through KIT-independent mechanisms, in which KIT expression is lost in progressing tumors, often being associated with phenotypic changes. 6, 9 This phenomenon of receptor tyrosine kinase switch, which results in KIT being removed from driving cell growth, remains to be further elucidated. Although, 1 in vitro study implicated AXL receptor tyrosine kinase in substituting KIT to induce imatinib resistance in GIST882 cells, 22 others have not been able to validate these findings.
As the presence of second-site mutations in KIT has been associated with KIT hyperactivation-driven mechanisms of resistance, it is not surprising that KIT-negative dedifferentiation is not triggered through similar pathways. Interestingly, half of the cases included in this study showed a wild-type genotype, suggesting preferential escape from KIT addiction in tumors that exhibit oncogenic KIT signaling through mechanisms other than activating mutations. Furthermore, it has been previously shown that in contrast to KIT-mutant GIST, the wild-type tumors develop imatinib resistance in the absence of acquired KIT mutations, through yet undefined mechanisms. 20, 23 The results of the present study show that LOH, with common loss of 1 KIT gene copy, was the prevalent finding in KITindependent tumor progression on imatinib therapy. Thus, loss of KIT expression due to haploinsufficiency was found in all 3 cases of CD117-negative dedifferentiated GIST detected in imatinib-resistant patients. Remarkably, in 2 patients with de novo dedifferentiation, a low level of KIT amplification was noted, suggesting that oncogene expression is not necessarily regulated by gene dosage, and other potential mechanisms, such as KIT promoter methylation or miRNA, may play a role in this phenomenon. In summary, we provide a detailed molecular characterization of CD117-negative dedifferentiated GIST, compared with the CD117-positive conventional GIST component. In addition to dedifferentiation in GIST occurring secondary to chronic KIT inhibition and imatinib resistance, we provide evidence for this phenomenon developing as de novo progression. Furthermore, we expand the morphologic spectrum of these tumors to report, for the first time, a phenotypic shift to angiosarcomatous histology. We also report the presence of a KRAS G12V mutation which coexisted with a KIT exon 11 mutation in one of the dedifferentiated GISTs, in the setting of prolonged chronic inhibition of KIT signaling due to therapy for CML. However, overall the process of dedifferentiation is not associated with acquisition of additional mutations in the original driver oncogene. Instead, our findings suggest that genetic instability, represented either by LOH or low-level amplification of KIT, is a common abnormality in the CD117negative dedifferentiated component. The remarkable morphologic and immunophenotypic changes present in the CD117-negative anaplastic component can pose significant challenges to the practicing pathologist, eventually resulting in misdiagnoses. The previous history of GIST and/or tyrosine kinase inhibitor therapy should be a hint in raising the suspicion of dedifferentiation in GIST. It is tempting to speculate that KIT silencing may induce loss of the conventional GIST phenotype and abrogation of the common signaling pathway.
